## Pharmacy Prior Authorization

## AETNA BETTER HEALTH ILLINOIS FAMILY HEALTH PLAN (MEDICAID)

Daliresp (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at **1-844-242-0908**.

When conditions are met, we will authorize the coverage of Daliresp (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug	Name (please circle)			
Dalire	esp (roflumilast)			
Othe	r, please specify			
Quar	ntity	Frequency S	trength	
Route of Administration		Expected Length of therapy		
Pati	ent Information			
Patie	nt Name:			
Patie	nt ID:			
Patie	nt Group No.:			
Patie	nt DOB:			
Patie	nt Phone:			
Pres	scribing Physician			
Phys	ician Name:			
Spec	ialty:	NPI Number:		
Phys	ician Fax:	Physician Phone:		
Phys	ician Address:	City, State, Zip:		
Diag	ınosis:	ICD Code:		_
Pleas	e circle the appropriate answe	er for each question.		
1.		authorized this medication in the past for this horization is on file under this plan)?	s Y	N
	[If no, then skip to question	on 3.]		
2.	Has the patient had a desince starting Daliresp?	crease in the number of COPD exacerbation	s Y	N
	[No further questions]			
3.	Does the patient have a bronchitis?	diagnosis of severe COPD with chronic	Υ	N

Reference Number: C7981-C/ Effective Date: 12/01/2017

Col	mments:		
9.	Is the patient 18 years of age or older?	Υ	N
	[If yes, then no further questions]		
8.	Does the patient have moderate to severe liver impairment (Child-Pugh B or C)?	Υ	N
	[If no, then no further questions.]		
7.	Has the patient had an intolerance or contraindication to the following: A) a LABA (long-acting beta-agonist) PLUS a LAMA (long-acting muscarinic antagonist), B) a LABA PLUS an ICS (inhaled corticosteroid)?	Y	N
	[If yes, then skip to question 8.]		
6.	Will the patient continue to use Daliresp with either of the following: A) a LABA (long-acting bronchodilator) PLUS a LAMA (long-acting muscarinic antagonist), B) a long-acting beta-agonist (LABA) PLUS an inhaled corticosteroid (ICS)?	Y	N
	[If no, then no further questions.]		
	If yes, list name(s) of products tried:		
5.	Has the patient experienced an inadequate treatment response, intolerance, or contraindication to a 3 month trial of any of the following: A) a long-acting bronchodilator (LABA) plus a long-acting muscarinic antagonist (LAMA) plus an inhaled corticosteroid (ICS), B) a long-acting beta-agonist (LABA) plus an inhaled corticosteroid (ICS)?	Υ	N
	[If no, then no further questions.]		
4.	Did the patient have symptomatic COPD exacerbations within the last year?	Y	N

Reference Number: C7981-C/ Effective Date: 12/01/2017

**Prescriber (Or Authorized) Signature** 

Date